β-AMYLOID IN PLASMA ABTEST-SERVICE

ABtest Service

Numerous results from different laboratories and different assays now show that plasma levels of Aβ40/Aβ42 reflect the brain amyloid burden, considered to be the first pathological change associated with Alzheimer’s disease (1).

Determining the plasma levels of these peptides could help in the diagnosis and prognosis of AD, especially in people who are still asymptomatic (2).

In addition, the use of these plasma tests as pre-screening (triage) tools could make it much easier and cheaper to recruit these individuals into clinical trials of new treatments that seek to modify the course of the disease by halting or delaying the onset of symptoms.

Araclon Biotech has been committed since its foundation to the development of blood biomarkers in order to help in the diagnosis of Alzheimer’s disease. Along these lines we have developed analysis procedures for the quantification in plasma* of Aβ40 and Aβ42 peptides (ABtestService) whose accumulation in the brain is considered to be the first pathological change related to Alzheimer’s disease (1).

Automated service

ABtestService guarantees reliable results from automated analysis by immunoassay (ABtest-IA) or by mass spectrometry (ABtest-MS) under strictly standardised conditions and performed by highly qualified personnel.

We do not sell kits, rather we offer a testing service (ABtestService). You only have to send us your plasma (or Cerebrospinal Fluid) samples (*).

ABtestService has already been tested in different cohorts globally.

(*) Frozen plasma samples, ideally at -80°C, should be submitted to our laboratory. ABtestService only needs 250 microlitres of plasma for the determination of the Aβ42/Aβ40 ratio.

Whole blood (minimum sample volume 500 microlitres) collected in EDTA K2 tubes is also acceptable if refrigerated immediately after collection and delivered to our laboratory within 30 hours. Our assays are optimised for plasma but are also viable in blood serum.

Araclon Biotech is deeply committed to quality, the company has a strict quality control system certified ISO 9001 (2015) and ISO 13485 (2016) and SOPs established for all processes, including supplier auditing.

ABtestService guarantees reliable results from automated analysis by immunoassay (ABtest-IA) or mass spectrometry (ABtest-MS).

ABtest service is offered in the USA under the USABtest® registered trademark.

ABtestService can be arranged in two different modalities, ABtest-IA and ABtest-MS.

Analytically speaking, both procedures, ABtest-IA and ABtest-MS, are fully validated.

ABtest-IA is currently CE marked in the EU and Investigational Use Only (IUO) labelled in the rest of the world.

ABtest-IA

Robotic service for the determination of Aβ42 and Aβ40 peptides in plasma by means of Araclon's patented colorimetric Sandwich ELISA.

Semi-automatic service for Aβ42 and Aβ40 plasma proteins quantitation by means of a colorimetric Sandwich ELISA Sandwich patented by Araclon.

ABtest-MS

Service for the determination of Aβ42 and Aβ40 peptides in plasma by liquid chromatography tandem mass spectrometry assay patented by Araclon.

Service for Aβ42 and Aβ40 plasma proteins quantitation trough a Liquid chromatography tandem mass spectrometry assay patented by Araclon.

References:

1. Gouras GH, Olsson Tand Hansson O. β-amyloid Peptides and Amyloid Plaques in Alzheimer’s Disease. Neurotherapeutics. 2015; 12:3-11. https://pubmed.ncbi.nlm.nih.gov/25371168
2. Bateman RJ et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012; 367:795-804. https://pubmed.ncbi.nlm.nih.gov/22784036